Treating Schizophrenia by Correcting Abnormal Brain Development

• Status: Active, not recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease.

This study is funded by the National Institutes of Health.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Collaborator: Dartmouth-Hitchcock Medical Center
• Treatments: Antipsychotic Agents; Tiagabine

Criteria

Inclusion Criteria:

• Meets criteria for the diagnosis of schizophrenia, with onset of psychotic symptoms within the past 3 years.

• Currently on second-generation antipsychotics for at least 3 months.

• Age 18-25, otherwise healthy.

Exclusion Criteria:

• Diagnosis of schizoaffective disorder.

• Has failed two or more clinically adequate antipsychotic trials.

• History of seizures or any neurologic disorders.

• Pregnant or nursing women.

• Known HIV infection.

• Actively suicidal.

• History of any substance dependence.

• Currently meets criteria for substance abuse/dependence.

• Other MRI exclusion criteria per Radiology Department protocols.